WO2000039275A2 - Multiple shear stress responsive elements (ssre) and methods of use thereof - Google Patents
Multiple shear stress responsive elements (ssre) and methods of use thereof Download PDFInfo
- Publication number
- WO2000039275A2 WO2000039275A2 PCT/IL1999/000702 IL9900702W WO0039275A2 WO 2000039275 A2 WO2000039275 A2 WO 2000039275A2 IL 9900702 W IL9900702 W IL 9900702W WO 0039275 A2 WO0039275 A2 WO 0039275A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- shear stress
- vector
- stress response
- response element
- pdgf
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 119
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 235
- 230000033115 angiogenesis Effects 0.000 claims abstract description 48
- 230000004862 vasculogenesis Effects 0.000 claims abstract description 29
- 230000003938 response to stress Effects 0.000 claims description 211
- 108091027981 Response element Proteins 0.000 claims description 207
- 239000013598 vector Substances 0.000 claims description 205
- 150000007523 nucleic acids Chemical class 0.000 claims description 150
- 102000039446 nucleic acids Human genes 0.000 claims description 137
- 108020004707 nucleic acids Proteins 0.000 claims description 137
- 210000002889 endothelial cell Anatomy 0.000 claims description 88
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 230000014509 gene expression Effects 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims description 53
- 230000015572 biosynthetic process Effects 0.000 claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 47
- 210000004204 blood vessel Anatomy 0.000 claims description 44
- 210000005166 vasculature Anatomy 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 35
- 230000000692 anti-sense effect Effects 0.000 claims description 27
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 26
- 238000003786 synthesis reaction Methods 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 25
- 230000004936 stimulating effect Effects 0.000 claims description 25
- 108090000994 Catalytic RNA Proteins 0.000 claims description 24
- 102000053642 Catalytic RNA Human genes 0.000 claims description 24
- 108091092562 ribozyme Proteins 0.000 claims description 24
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 23
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 22
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 21
- 108010021466 Mutant Proteins Proteins 0.000 claims description 21
- 102000008300 Mutant Proteins Human genes 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 21
- 239000003085 diluting agent Substances 0.000 claims description 21
- -1 NFAT Proteins 0.000 claims description 20
- 230000004663 cell proliferation Effects 0.000 claims description 19
- 230000035800 maturation Effects 0.000 claims description 19
- 230000002491 angiogenic effect Effects 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 15
- 239000003102 growth factor Substances 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 108700008625 Reporter Genes Proteins 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 208000019553 vascular disease Diseases 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 10
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 9
- 108060001084 Luciferase Proteins 0.000 claims description 8
- 230000002885 thrombogenetic effect Effects 0.000 claims description 8
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 230000002222 downregulating effect Effects 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 7
- 230000000982 vasogenic effect Effects 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 239000003527 fibrinolytic agent Substances 0.000 claims description 6
- 230000003480 fibrinolytic effect Effects 0.000 claims description 6
- 230000008728 vascular permeability Effects 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 230000001732 thrombotic effect Effects 0.000 claims description 5
- 102000035160 transmembrane proteins Human genes 0.000 claims description 5
- 108091005703 transmembrane proteins Proteins 0.000 claims description 5
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims description 4
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 4
- 108010031896 Cell Cycle Proteins Proteins 0.000 claims description 3
- 102000005483 Cell Cycle Proteins Human genes 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 3
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims description 3
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims description 3
- 239000005089 Luciferase Substances 0.000 claims description 3
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 claims description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 3
- 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 claims description 2
- 102100031478 C-type natriuretic peptide Human genes 0.000 claims description 2
- 108010024212 E-Selectin Proteins 0.000 claims description 2
- 102100023471 E-selectin Human genes 0.000 claims description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims description 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims description 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 2
- 241000714474 Rous sarcoma virus Species 0.000 claims description 2
- 241000700565 Swinepox virus Species 0.000 claims description 2
- 102000002938 Thrombospondin Human genes 0.000 claims description 2
- 108060008245 Thrombospondin Proteins 0.000 claims description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 2
- 241000700618 Vaccinia virus Species 0.000 claims description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 2
- 210000001043 capillary endothelial cell Anatomy 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims 1
- 108010093031 Galactosidases Proteins 0.000 claims 1
- 239000013604 expression vector Substances 0.000 abstract description 9
- 230000035882 stress Effects 0.000 description 88
- 210000001519 tissue Anatomy 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 28
- 239000000203 mixture Substances 0.000 description 27
- 238000011282 treatment Methods 0.000 description 18
- 230000003511 endothelial effect Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 238000001890 transfection Methods 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000000004 hemodynamic effect Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 230000000302 ischemic effect Effects 0.000 description 11
- 239000002502 liposome Substances 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 10
- 239000003623 enhancer Substances 0.000 description 10
- 239000003446 ligand Substances 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 210000003038 endothelium Anatomy 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000009618 Transforming Growth Factors Human genes 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000007910 cell fusion Effects 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 108700039887 Essential Genes Proteins 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 238000002399 angioplasty Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- 230000007998 vessel formation Effects 0.000 description 5
- 108020004638 Circular DNA Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 229920000249 biocompatible polymer Polymers 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 102100034608 Angiopoietin-2 Human genes 0.000 description 3
- 108010048036 Angiopoietin-2 Proteins 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 3
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000013020 embryo development Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001638 lipofection Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102000009088 Angiopoietin-1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102100036448 Endothelial PAS domain-containing protein 1 Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 102000054727 Serum Amyloid A Human genes 0.000 description 2
- 108700028909 Serum Amyloid A Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102000012753 TIE-2 Receptor Human genes 0.000 description 2
- 108010090091 TIE-2 Receptor Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000006467 collateral growth Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000013154 diagnostic monitoring Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010017007 glucose-regulated proteins Proteins 0.000 description 2
- 230000002706 hydrostatic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011253 protective coating Substances 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000003639 vasoconstrictive effect Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- USZKOIUIZMUMSE-UHFFFAOYSA-N 1h-pyrrole-2-sulfonamide Chemical class NS(=O)(=O)C1=CC=CN1 USZKOIUIZMUMSE-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 description 1
- DICULBYFSUXYAH-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CC(=C)C(=O)OCCO DICULBYFSUXYAH-UHFFFAOYSA-N 0.000 description 1
- JIDQLRAXHLEPIW-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C.CC(=C)C(=O)OCCO JIDQLRAXHLEPIW-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 101710177847 Actin, muscle Proteins 0.000 description 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100032381 Alpha-hemoglobin-stabilizing protein Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000036490 Arterial inflammations Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010077078 Creatinase Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 102100039328 Endoplasmin Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000014061 Extranodal Extension Diseases 0.000 description 1
- 208000036376 Femoral artery occlusion Diseases 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101710121996 Hexon protein p72 Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000797984 Homo sapiens Alpha-hemoglobin-stabilizing protein Proteins 0.000 description 1
- 101000851937 Homo sapiens Endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 101000829902 Homo sapiens G-protein coupled estrogen receptor 1 Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100024573 Macrophage-capping protein Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101710155216 Methylamine dehydrogenase heavy chain Proteins 0.000 description 1
- 101710183893 Methylamine dehydrogenase light chain Proteins 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 1
- 229940123989 Purinoreceptor antagonist Drugs 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 201000003099 Renovascular Hypertension Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102100026966 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102100029290 Transthyretin Human genes 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000005249 arterial vasculature Anatomy 0.000 description 1
- 230000001623 arteriogenic effect Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 206010049444 fibromatosis Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000047823 human PLAT Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000013147 laser angioplasty Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108010042121 probasin Proteins 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008698 shear stress Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000012612 static experiment Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000006354 stress signaling Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001604 vasa vasorum Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Definitions
- This invention provides expression vectors comprising multiple shear stress responsive elements and a gene of interest or nucleic acid encoding the protein or peptide of interest. Further, this invention provides methods to monitor shear stress activities, to screen and select for target genes and methods of identifying and describing genes which are differentially expressed in disease states. Lastly, this invention provides methods for methods for treating disorders by introducing the vector into the vasculature which has hemodynamic forces such as fluid shear stress forces; diagnostic methods for monitoring of patients undergoing clinical evaluation for the treatment of disease and for the identification, monitoring and therapeutic use of compounds as treatments of disease.
- vasculogenesis the establishment of vascular network during embryogenesis from multipotential mesanchymal progenitors
- angiogenesis the sprouting of existing blood vessels which occurs both in the embryo and in the adult (1-5).
- Endothelial cells are the major players in both processes, they migrate and proliferate and then assemble into tubes with tight cell-cell connections. Peri-endothelial cells are recruited to support the endothelial tube, providing maintenance and modulatory functions to the vessel. These cells are perycytes in the capillaries, smooth muscle cells in larger vessels and cardiac mycocytes in the heart.
- VEGF Vascular Endothelial Growth factor
- Angiopeitin 1 and 2 and their receptor Tiel and 2
- bFGF Basic Fibroblast Growth Factor
- PDGF Platelet derived Growth factor
- TGF Transforming Growth Factor
- angiopoietin 1 and 2 were disrupted (10-14), endothelial cells organized into a tube shape, but failed to recruit the periendothelial cells.
- endothelial cells In mature blood vessels, endothelial cells, by virtue of their unique anatomical position, are constantly exposed to the fluid mechanical forces generated by the flowing blood (See, William R. Milnor in Chapter 6 entitled “The Normal Hemodynamic State” of the book entitled “Hemodynamics”, published by Williams & Wilkins, Maryland (1989) and US Patent Nos. 5199298, 5052228 and 4926696 for measuring shear stress.
- hemodynamic forces which include hydrostatic pressure, cyclic strain and frictional wall shear stress, constitute a special category of physical stimuli that, in addition to better characterized biochemical stimuli, can elicit important biological responses in the cells that compose the blood vessel wall (23).
- ischemic foot (as a result of femoral artery occlusion) where collaterals develop in both ischemic and more distant non-ischemic regions (34).
- ischemic foot (as a result of femoral artery occlusion) where collaterals develop in both ischemic and more distant non-ischemic regions (34).
- angiogenesis often involves massive sprouting of the already existing vessels, which is accompanied by the regression of some of the newly formed tubes (21,22). Is this balance (formation versus regression) affected by changes in the rate and pattern of blood flow through these newly formed tubes?
- This invention provides a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide.
- the genes code for transcription factors, cell cycle proteins, signaling molecules, degrading proteins, transmembrane protein, enzyme, secreted factors, growth factor, angiogenic factor, or thrombogenic factor. It is contemplated herein, that the vector comprises one or a multiple number of genes.
- This invention provides a method for detecting shear stress or a shear stress related condition in a subject, comprising administering to the subject an amount of the vector which comprises one or more Shear Stress Response Element (SSRE) and a gene of interest coupled to the SSRE, wherein the gene is activated in a shear stress environment, thereby detecting shear stress or a shear stress related condition in the subject.
- SSRE Shear Stress Response Element
- This invention provides methods to monitor shear stress activities, to screen and select for target genes and methods of identifying and describing genes which are differentially expressed in disease states, relative to their expression in normal, or non disease states and a method for the identification and therapeutic use of compounds as treatments of the disease.
- this invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of diseases, such as cardiovascular, neoplastic, vascular associated_ diseases, and for monitoring the efficacy of compounds in clinical trials.
- This invention provides gene therapy methods for treating disorders related to or associated with vasculogenesis and/or angiogenesis by introducing the vectors described herein in the vasculature having hemodynamic forces such as fluid shear stress forces.
- Hemodynamic forces which include hydrostatic pressure, cyclic strain, and frictional wall shear stress, play an important role in the formation and maturation of blood vessels by regulating endothelial genes through Shear Stress Responsive Elements (SSRE) in promoters of endothelial shear stress responsive genes.
- SSRE Shear Stress Responsive Elements
- the vectors provided herein are useful as acting as agents or in combination with other therapeutic agents for inhibiting, stimulating, regulating and/or modulating a variety of cellular processes (e.g., vasculogenic, angiogenic -related and/or metabolic-related processes).
- This invention provides a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an inhibitor or repressor of the gene of interest, wherein the nucleic acid is an antisense molecule which hybridizes with the sense RNA strand made by the gene and thereby inhibit synthesis of the corresponding gene, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide.
- SSRE Shear Stress Response Elements
- the promoter Shear Stress Response Elements are nucleic acid sequences from regulatory elements of growth factors, thrombogenic factors or angiogenic genes.
- This invention provides for a vector which comprises a multiple number of Shear Stress Response Elements which binds to NFKB, NFAT, SP1, or Egrl and/or Shear Stress Response Element which comprises a binding site for fos, jun, or SP1.
- the vector comprises a gene of interest or a nucleic acid encoding one or more transmembrane proteins, enzymes, secreted factors, or a gene coding for any protein. Further, the vector may comprises a reporter gene, or a selection marker.
- This invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide and a suitable diluent or carrier.
- SSRE Shear Stress Response Elements
- This invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Sheaf Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier.
- SSRE Sheaf Stress Response Elements
- This invention provides a method of inhibiting endothelial cell proliferation comprising transfecting the endothelial cells with an effective amount of a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier; or a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, wherein the Shear Stress Response Element
- This invention provides a method of modulating vascular permeability in a mammal, comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide and a suitable diluent or carrier; or a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier, wherein the pharmaceutical composition is administered to the mammal in the vasculature with the proviso that the vasculature has shear stress forces, so as to permit the Shear Stress Response Element
- This invention provides a method of stimulating the formation, maturation or regression of blood vessels of a subject, comprising administering to said subject an effective amount of a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide and a suitable diluent or carrier, wherein the pharmaceutical composition is administered to the mammal in the vasculature with the proviso that the vasculature has shear stress forces, so as to permit the Shear Stress Response Elements to be activated by the shear stress and transcriptionally regulate endothelial cell gene expression, thereby stimulating the formation, maturation or regression of blood vessels.
- SSRE Shear Stress Response Elements
- This invention provides a method of inhibiting the formation, maturation or regression of blood vessels of a subject, comprising administering to said subject an effective amount of a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier; or a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, wherein the pharmaceutical composition or the
- This invention provides a method of modulating genes or proteins involved in a diseases which comprises administering to a subject with the disease an effective amount of the pharmaceutical compositions and/or vectors described, above, wherein the pharmaceutical composition or vector is administered to the subject in the vasculature with the proviso that the vasculature has shear stress, so as to permit the Shear Stress Response Elements to be activated by the shear, thereby modulating genes or proteins involved in the vascular diseases.
- a method of down regulating angiogenesis comprising administering to the subject an amount of a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier; or a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, wherein the pharmaceutical composition or the vector is administered to the mammal in the vasculature with the proviso that the
- the present invention relates to a method for revascularization of ischemic tissues, development of collateral vessels and improvement of function in peripheral and myocardial ischemic tissue and enhancing the level of perfusion of blood to a target tissue. Also, the present invention relates to a method for treating a target tissue suffering from or at risk of suffering from ischemic damage, and a method of inducing angiogenesis in a target tissue.
- This invention provides a method of inhibiting endothelial cell proliferation comprising transfecting the endothelial cells with an effective amount of the vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an inhibitor or repressor of the gene of interest, wherein the nucleic acid is an antisense molecule which hybridizes with the sense RNA strand made by the gene and thereby inhibit synthesis of the corresponding gene, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, wherein SSRE is two or more or a combination of Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear " Stress Response Element TRE and Shear Stress Response Element SP1 , such that the Shear Stress Response Element transcriptionally regulate endothelial cell gene expression, thereby
- This invention provides a method of stimulating endothelial cell proliferation comprising transfecting the endothelial cells with an effective amount of the vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide, wherein the SSRE is Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SP1, and Shear Stress Response Element TRE, wherein the Shear Stress Response Element transcriptionally regulate endothelial cell gene expression, thereby stimulating endothelial cell proliferation.
- SSRE Shear Stress Response Element
- PDGF-B Shear Stress Response Element PDGF-B
- Shear Stress Response Element SP1 Shear Stress Response Element SP1
- Shear Stress Response Element TRE Shear Stress Response Element transcriptionally regulate endothelial cell gene expression
- This invention provides a method of stimulating angiogenesis comprising contacting the cells with an effective amount of the vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide, wherein the SSRE is Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SP1, and Shear Stress Response Element TRE, thereby stimulating angiogenesis.
- SSRE Shear Stress Response Element
- PDGF-B Shear Stress Response Element PDGF-B
- Shear Stress Response Element SP1 Shear Stress Response Element SP1
- Shear Stress Response Element TRE Shear Stress Response Element TRE
- This invention provides a method for screening test compounds for the ability to regulate endothelial cell expression or angiogenesis and/or vasculogenesis comprising: (a) contacting a endothelial cells with the compound to be tested; (b) determining the amount or expression of the endothelial cells or the amount of angiogenesis and/or vasculogenesis produced as a result of the test compound; (c) stimulating endothelial cells by introduction of the vector provided herein; (d) determining the amount or expression of the endothelial cells or the amount of angiogenesis and/or vasculogenesis produced as a result of the vector; (e) comparing the amount of angiogenesis and/or vasculogenesis produced as a result step (b) to that of step (d), wherein an increased amount of expression of the endothelial cells or the amount of angiogenesis and/or vasculogenesis of the test compound means that the test compound regulates endothelial cell expression angiogenesis and/or vasculogenesis.
- Figure 1 Schematic of a SSRE hybrid promoter vector named pGL2 -promoter vector (5789 bases) comprising one of the following: NR1/2+NR3/4; NR1/2; or
- NR3/4 promoter, poly(A) signal and a reporter gene.
- NR1/2 comprises nucleic acid sequences of two (2) PDGF-B SSRE, a Sp-1, and TRE, while
- NR3/4 comprises nucleic acid sequences of Sp-l/Egr-1 and TRE.
- Figure 2 Schematic of a SSRE hybrid promoter vector named pGL3-enahncer vector (5255 bases) comprising one of the following: NR3/4 and NR1/2+ NR3/4, poly(A) signal and a reporter gene.
- shear stress responsive promoter elements Several novel shear stress response elements have been defined herein, that bind endothelial cells transcription factors which are activated by shear stress forces.
- "synthetic" shear stress responsive elements have been constructed containing SSREs which have been tested under laminar shear stress regimes and patterns.
- Shear stress includes pulsatile, turbulent, oscillatory, disturbed LSS, shear stress gradients.
- shear stress is important modulators of cellular functions in many tissues and particular important in the cardiovascular system to maintain homeostasis of blood vessels.
- shear stress is a laminar steady state force, different than those acting at the branch points of the blood vessels.
- complex shear stresses are involved in the development of cardiovascular diseases such as atherosclerosis and hypertension. Development of such pathologies are thought to be initiated by function/dysfunction of vascular endothelial cells.
- the vascular endothelium constitutes the interface between the blood and the vessel wall, as such, it is exposed to mechanical forces produced by the arterial pressure variations during the cardiac cycle, and i.e., the blood flow induced wall shear stress and the circumferential cyclic stretch of the whole vessel wall.
- Blood flow interaction with the vascular endothelium represent a specialized example of mechanical regulation of cell function that has important physiological and pathological consequences. Blood flow plays an important role in the morphogenesis of blood vessels, for instance increase in blood flow induces dilation of the blood vessels while decrease in blood flow cause reduction in blood vessel diameter.
- Vessel remodeling occurs in response to both biochemical and biomechanical stimuli, and has been shown to be dependant on the presence of an intact endothelial layer.
- endothelial cells are constantly exposed to hemodynamic forces generated by the flowing blood, forces that consist of fluid shear stress, cyclic strain and pressure. These forces affect endothelial cells structure and function, changes that are often mediated by the induction or shut-off of endothelial genes.
- This invention provides a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide.
- the genes code for transcription factors, cell cycle proteins, signaling molecules, degrading proteins, transmembrane protein, enzyme, secreted factors, growth factor, angiogenic factor, or thrombogenic factor. It is contemplated herein, that the vector comprises multiple genes.
- the vector comprising a nucleic acid or gene coupled to the SSRE which encodes a peptide or protein. Any gene or nucleic acid encoding a protein or peptide may be used. In one embodiment the nucleic acid or gene which encodes a peptide or protein which is angiogenic and/or vaculogenic. Angiogenic genes and proteins are known to those skilled in the art.
- the nucleic acids encodes the following proteins or growth factors: NFkB, MCP-1, NFAT, spl/Egr 1, c-fos, c-jun, c-myc, PDGF A, PDGF B, TM, b-FGF, TGF, eNOS, HO-1, cu/Zn SOD, VCAM-1, I-CAM, Connecxin 43, FLT-1 , FLK-1, VCAM, PGI synthase, smad 6, smad 7, TGF.
- proteins or growth factors include NFkB, MCP-1, NFAT, spl/Egr 1, c-fos, c-jun, c-myc, PDGF A, PDGF B, TM, b-FGF, TGF, eNOS, HO-1, cu/Zn SOD, VCAM-1, I-CAM, Connecxin 43, FLT-1 , FLK-1, VCAM, PGI synthas
- HB-EG CNP COX-2, thrombospondin, ICAM, ELAM-1, cyclooxygenase, angiopeitin 1, tenscin, angiopeitin 2, laminin Bl, IL-1, 11-2, 11-3, 11-4, 11-4, IL-6, 11-7, 11-8, 11-9. 11-10, 11-1 1 , 11-12, ACE , ICE, Vascular Endothelial Growth Factor (VEGF) Genbank Accession Nos: 2851617, 1718152, 137821. 3402014, 3402011, 3402013, 3402010.
- VEGF Vascular Endothelial Growth Factor
- PLGF-l/PLGF-2 Placenta Growth Factor 1 and 2 Genbank Accession No: 1709656, EPAS-1 Genbank Accession No:391429, EEGIR-3 Genbank Accession No. 1718189, FLT-1 Genbank Accession No.
- EDRF Endothelin-Derived Relaxin Factor
- HGF/SF hepatocyte growth factor/Scatter factor
- PD-ECGF Platelet Derived Endothelial Cell Growth Factor
- uPA Urokinase Plasminogen Activator
- Cartillage Type II Collagen a tumor suppressor gene, tyrosine kinases, or serine kinases.
- the vector comprises alleles, alternative-splicing products, analogs, fragments, isoenzymes, mimetics, mutants, synthetic forms or variants of the nucleic acid. Additional genes, proteins are described in U.S.
- the angiogenic genes or proteins include natural and recombinant forms of a variety of peptides, e.g. growth factors and related molecules which are able to promote endothelial and smooth muscle cell proliferation leading to the formation of new blood vessels (angiogenesis).
- This invention provides a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule which hybridizes with the sense RNA strand made by the gene and thereby inhibit synthesis of the corresponding gene, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of. or activity of the protein or peptide,.
- This invention contemplates molecules which inhibit trans acting factors from combining with the promoter of endogenic gene. For example, by creating a promoter which contains target elements for binding trans acting factors which will then compete for these trans acting factors.
- the Shear Stress Response Elements (SSRE) of the vectors described herein are from regulatory elements of growth factors, thrombogenic factors or angiogenic genes.
- the vector may comprises a reporter gene, or a selection marker.
- the nucleic acids are in a sense orientation. In another embodiment the nucleic acids are in a sense or an anti-sense orientation. Each of the nucleic acids may be in a 5' to 3' direction in the vector or may be in a 3' to 5' direction in the vector.
- Shear Stress Response Element or “SSRE” means a nucleic acid from the regulatory elements of genes which regulates endothelial genes through shear stress forces.
- the gene may encode for growth factors, thrombogenic factors or angiogenic genes.
- a SSRE is an element necessary and/or sufficient to induce (or suppress) gene expression in endothelial cells exposed to shear stress.
- the vector comprises a single nucleic acid of the SSRE or multiple SSREs.
- the vector comprises the Shear Stress Response Element PDGF-A.
- the vector comprises the Shear Stress Response Element PDGF-B.
- the vector comprises the Shear Stress Response Element TRE.
- the vector comprises the Shear Stress Response Element SPl. In another embodiment the vector comprises the Shear Stress Response Element PDGF-A and the Shear Stress Response Element PDGF-B. In another embodiment the vector comprises the Shear Stress Response Element PDGF-A and the Shear Stress Response Element TRE. In another embodiment the vector comprises the Shear Stress Response Element PDGF-B and the Shear Stress Response Element TRE. In another embodiment the vector comprises the Shear Stress Response Element PDGF-A and the Shear Stress Response Element SPl. In another embodiment the vector comprises the Shear Stress Response Element PDGF-B and the Shear Stress Response Element SP 1.
- the vector comprises multiple number of SSREs.
- the vector comprises the Shear Stress Response Element are Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TRE.
- the Shear Stress Response Elements are Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element TRE
- the Shear Stress Response Elements are Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl .
- this invention provides for a vector which comprises a mutiple number of different combinations of the Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TRE including but not limited to multiple combinations of each SSRE.
- this invention provides for a SSRE which binds to NFKB, NFAT, SPl, or Egrl. Further, this invention provides for a nucleic acid of a regulatory element or region which contains one or more the SSRE. This invention provides for SSRE which are binding sites for fos, and jun.
- SSRE PDGF-A means a Platelet Derived Growth Factor- A which comprises the nucleic acid sequence as follows: GGGGGCGGGGGCGGGGG (SEQ ID NO. 1).
- SSRE PDGF-B means a Platelet Derived Growth Factor- B which comprises the nucleic acid sequence as follows: GAGACC (SEQ ID NO. 2).
- SSRE TRE means a nucleic acid which has the following sequence TGACTCC (SEQ ID NO. 3).
- SSRE SPl means a nucleic acid which has the following sequence GGGGCGGGCGG (SEQ ID NO. 4).
- the vector comprises the following nucleic acid sequence CGCCTGAGACCCCCGGGGCGGGGCGGAGACCCCCTGACTCCCCACTCTGGG GGCCCCGCCCCGCCTCTGGGGGACTGAGGGAGCT (SEQ ID NO 5).
- the vector comprises the following nucleic acid sequenceTCGAGGGGGGCGGGGGCGGGGGGGTGACTCCGAGACCCCCACCCCCCG CCCCCGCCCCCACTGTGGCTCTGGGGGTCTAG (SEQ ID NO 6).
- the vector comprises the following nucleic acid sequence CGCCTGAGACCCCCGGGGCGGGGCGGAGACCCCCTGACTCCCCACTCTGGG GGCCCCGCCCCGCCTCTGGGGGACTGAGGGAGCTTCGAGGGGGGCGGGGGC GGGGGTGACTCCGAGACCCCCACCCCCCGCCCCCCCCCCCACTGTGGCTCTG GGGGTCTAG (SEQ ID NO 7).
- SSREs of the promoter elements from genes that are regulated by shear stress include but are not limited to: Human 15-lipoxygenase gene, Genebank Accession No. U88317 at position 3350..3355, Kritzik,M.R., Ziober.A.F., Sigal,E. and Conrad.D.J., Biochim. Biophys. Acta (1997); Protein Kinase, Genbank Accession No. 2992634, Donadelli,R., Benatti,L., Remuzzi ., Morigi M., Gullans,S.R., Benigni,A., Remuzzi,G. and Noris,M. Biochem. Biophys. Res. Commun.
- FEG-1 gene which is expressed by vascular endothelial cells under shear stress., Genbank Accession No. El 3350 and 3023539; Endothelin-converting enzyme (ECE-1) gene, Genbank Accession No. X91923 at position 233..238, Valdenaire,O, J. Biol. Chem. 270 (50), 29794-29798 (1995); and Beta-tubulin folding cofactor D, Genbank Accession No.
- AJ006417 PGI synthetase; conexin 43; c-myc; c-fos; c-jun; TGF; FGF; FGF; HO-1 ; Thrombomodulin; Tl rombospondin; Laminin Bl ; Mn/Cu/Zn SOD; ICAM-1 ; Endothlin-1 ; plasminogen activator 1 ; MADH dehydrogenase; acidic and basic fibroblast growth factors; vascular endothelial growth factors 1, 2, 3, A, B, C, and D; epidermal growth factor; transforming growth factors alpha and beta; tumor necrosis factor alpha; hepatocyte growth factor; vascular endothelium growth factor, EEGIR-3, FLT-1.
- VEGF vascular endothelial growth factor
- ESA computer analysis and electromobility shift assays
- the vector further comprising a reporter gene.
- Reporter genes are known to those skilled in the art.
- the vector may comprise the reporter gene with an SSRE without any additional nucleic acid which encodes a gene of interest or may include the nucleic acid which encodes a gene of interest.
- reporter genes include but are not limited to: ⁇ -lactamase and other antibiotic resistant gene, a cell surface marker as HC I or II sub-types, a receptor for growth factor or cell adhesion and any gene of interest for therapeutic reasons.
- the vector may comprise a marker inserted may provide for prototrophy to an auxotrophic host, biocide resistance, e.g., antibiotics, or heavy metals, such as copper, or the like.
- the selectable marker gene sequence can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection. Additional elements may also be needed for optimal . These elements may include splice signals, as well as transcription promoters, enhancers, and termination signals. cDNA expression vectors incorporating such elements include those described by Okayama, Molec. CelZ. Biol. 3:280(1983).
- the transcribed gene under the SSRE can be also a gene that confirm resistant to a specific antibiotic as a selection marker in prokaryotes and eukaryotes cells (neomycin, tetracycline. kanamycine and other).
- the gene can be also a membrane protein as a screening marker (MHC I or II sub-type or other transmembrane protein as a receptor);
- the gene can be also encoding for a protein in an individual carrying a genetic defective gene product to be complement for therapeutic reasons.
- the gene can be also a secreted protein (enzymes or growth factors) that can be monitored by an external or internal biosensor.
- One attractive gene to be driven by SSRE is a gene encoding a secreted protein with an enzyme activity that can be monitored with a biosensor.
- This protein can be driven by the second unit of a bicistronic massage driven by SSRE to give low amount of gene products, however indicative of the SSRE activity.
- For in-vivo gene delivery one can follow the activity of the second cistron to monitor on site (in-vivo) the first cistron.
- the second cistron include but not limited to lactate dehydrogenase, creatinase, esterase, alcohol dehydrogenase, all of which have characterized substrates and chemical reactions, and also enzymatic biosensor for such enzyme activities have been demonstrated in the art.
- a biosensor can be introduced in vivo to monitor SSRE activities for drug delivery or to be an indicative parameter of fluid shear stress.
- the SSRE vector could have one or more transcriptional units. For example, it can have an antibiotic selection marker and a Luciferase gene to monitor SSRE activity.
- the SSRE transcription unit can be monocistronic or bicistronic transcription unit, having IRES elements between the two genes.
- the SSRE vector can be used for selection of agonists and antagonists ligands, to shear stress signaling, from combinatorial peptide or antibody phage display libraries, for therapeutic means.
- natural inhibitors or stimulators from body fluids or other natural extracts
- this system can be used as an inducible system, to induce gene only when shear stress is applied. The methods described herein, provide functional screening (SSRE activity monitoring) and screening for target drug or target gene.
- Shear Stress Response Elements include but are not limited to, cDNA, DNA, fragments, variants, mutants, alleles, synthetic forms, both sense and antisense strands, and may be chemically or biochemically modified or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art so long as the SSRE retains its function, i.e. regulation of endothelial genes by shear stresses.
- Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), pendent moieties, intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and modified linkages (e.g., alpha anomeric nucleic acids, etc.).
- the nucleic acid may be modified.
- Such modifications include, for example, acetylation, carboxylation, phosphorylation, glycosylation, ubiquitination, labeling, e.g., with radionuclides, and various enzymatic modifications, as will be readily appreciated by those well skilled in the art.
- a variety of methods for labeling and of substituents or labels useful for such purposes are well known in the art, and include radioactive isotopes such as sup 32 P, ligands which bind to labeled antiligands (e.g., antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand.
- the choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation.
- This invention provides screening for mutation within the gene of interest coupled to the SSRE sequences so as to identify sequences with stronger SSRE- activity as shear stress dependent transcription sequences.
- the SSRE sequences may be screened for more potent binding proteins, as well for compounds that enhance or inhibit protein binding to SSRE for therapeutic means.
- nucleic acid refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules”) or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules”) and antisense, ribozyme, in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA, RNA, and RNA-RNA helices are possible.
- nucleic acid molecule refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms.
- this term includes double-stranded DNA found, inter alia, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes.
- sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
- a "recombinant DNA” is a DNA that has undergone a molecular biological manipulation.
- nucleic acid encoding refers to a nucleic acid molecule or gene which directs the expression of a specific protein or peptide.
- the nucleic acid sequences include both the DNA strand sequence that is transcribed into RNA and the RNA sequence that is translated into protein.
- the nucleic acid molecule include both the full length nucleic acid sequences as well as non-full length sequences derived from the full length protein. It being further understood that the sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell.
- Substantial identity or “substantial sequence identity” mean that two sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap which share at least 65-99 percent sequence identity, share at least 75 percent sequence identity, share at least 80 percent sequence identity, share at least 90 percent sequence identity, preferably at least 95 percent sequence identity, more preferably at least 99 percent sequence identity or more.
- This invention provides for a replicable vector comprising the isolated nucleic acid molecule.
- the vector includes, but is not limited to: a plasmid, cosmid, phage or yeast artificial chromosome (YAC) which contains at least a portion of the isolated nucleic acid molecule.
- insert and vector DNA can both be exposed to a restriction enzyme to create complementary ends on both molecules which base pair with each other and are then ligated together with DNA ligase.
- linkers can be ligated to the insert DNA which correspond to a restriction site in the vector DNA, which is then digested with the restriction enzyme which cuts at that site.
- Other means are also available and known to an ordinary skilled practitioner.
- vector refers to viral expression systems, autonomous self-replicating circular DNA (plasmids), and includes both expression and nonexpression plasmids. Where a recombinant microorganism or cell culture is described as hosting an "expression vector,” this includes both extrachromosomal circular DNA and DNA that has been incorporated into the host chromosome(s). Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host's genome.
- Expression vectors which can be used other than adenovirus include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus, swinepox virus, pox virus, rhabdovirus, herpes simplex virus, baculovirus, herpes simplex virus, adeno-associated virus, retrovirus, cytomegalovirus, human cytomegalovirus, papillomavirus, Epstein Barr virus (EBV), mouse mammary tumor virus (MMTV), Moloney murine leukemia virus and plasmid and cosmid DNA vectors, to name but a few.
- human or animal viruses such as vaccinia virus, swinepox virus, pox virus, rhabdovirus, herpes simplex virus, baculovirus, herpes simplex virus, adeno-associated virus, retrovirus, cytomegalovirus, human cytomegalovirus, papillomavirus, Epstein
- the adenoviral vector is deficient in at least one essential gene function of the El region of the adenoviral genome, particularly the Ela region, more preferably, the vector is deficient in at least one essential gene function of the El region and part of the E3 region (e.g., an Xbal deletion of the E3 region) or, alternatively, the vector is deficient in at least one essential gene function of the El region and at least one essential gene function of the E4 region.
- Aadenoviral vectors deficient in at least one essential gene function of the E2a or E2b region and adenoviral vectors deficient in all of the E3 region also are contemplated here and are well known in the art.
- the viral vector's coat protein can be modified so as to incorporate a specific protein binding sequence.
- plasmid refers to an autonomous circular DNA molecule capable of replication in a cell, and includes both the expression and nonexpression types. Where a recombinant microorganism or cell culture is described as hosting an "expression plasmid", this includes latent viral DNA integrated into the host chromosome(s). Where a plasmid is being maintained by a host cell, the plasmid is either being stably replicated by the cells during mitosis as an autonomous structure or is incorporated within the host's genome.
- a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG.
- a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome.
- Such vectors may be obtained commercially or assembled from the sequences described by methods well-known in the art, for example the methods described above for constructing vectors in general.
- Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.
- Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.
- a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in • a cell and initiating transcription of a downstream (3' direction) coding sequence.
- the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5 * direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
- a transcription initiation site (conveniently defined by mapping with nuclease SI), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
- Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT” boxes.
- Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the -10 and -35 consensus sequences.
- An "expression control sequence” is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence.
- a coding sequence is "under the control” of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.
- a nucleic acid sequence is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that DNA sequence.
- the term “operatively linked” includes having an appropriate start signal (e.g., ATG) in front of the DNA sequence to be expressed and maintaining the correct reading frame to permit expression of the DNA sequence under the control of the expression control sequence and production of the desired product encoded by the DNA sequence. If a gene that one desires to insert into a recombinant DNA molecule does not contain an appropriate start signal, such a start signal can be inserted in front of the gene.
- viral promoters include but are not limited to the following: ventricular myocyte specific promoter, cytomegalovirus, human cytomegalovirus, inflammatory promoters, TNF promoter, Rous Sarcoma Virus, Prostate Specific Antigen, Probasin, Immunoglobulin Heavy Chain, Immunoglobulin Light Chain, T-Cell Receptor, HLA, Interferon, Interleukin-2, Interleukin-2 Receptor, MHC Class II, Actin, Muscle Creatine Kinase, Proalbumin (Transthyretin), Elastase I, Metallothionein, Collagenase, Albumin Gene, Fetoprotein, Globin, c-fos, c-Ha-ras, Insulin, Neural Cell Adhesion Molecule (NCAM), antirypole, 2B (TH2B) Histone, Muse or Type I Collagen, Glucose
- This invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide and a suitable diluent or carrier.
- SSRE Shear Stress Response Elements
- This invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier.
- SSRE Shear Stress Response Elements
- Shear Stress Response Elements are from promoters of growth factors, thrombogenic factors or angiogenic genes.
- the pharmaceutical composition comprises any of the molecules described above.
- the vector of the pharmaceutical composition comprises nucleic acids of Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element TRE and Shear Stress Response Element SPl, or a vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, Shear Stress Response Element TRE, Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element TRE and Shear Stress Response Element SPl.
- the vector of the pharmaceutical composition comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TRE.
- the present invention provides a method of regulating endothelial cell proliferation or anti-proliferation using the vector comprising the SSRE and the gene of interest coupled to the SSRE.
- This invention provides a method of stimulating endothelial cell proliferation comprising transfecting the endothelial cells with an effective amount of the vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide wherein the Shear Stress Response Elements transcriptionally regulate endothelial cell gene expression, thereby stimulating endothelial cell proliferation.
- SSRE Shear Stress Response Elements
- endothelial cells are vascular endothelial cells or capillary endothelial cells.
- This invention provides a method of inhibiting endothelial cell proliferation comprising transfecting the endothelial cells with an effective amount of a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier; or a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, wherein the Shear Stress Response Element
- the SSRE of the vector comprises nucleic acids of Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element TRE and Shear Stress Response Element SPl , or a vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, Shear Stress Response Element TRE, Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element TRE and Shear Stress Response Element SPl, wherein the Shear Stress Response Element transcriptionally regulate endothelial cell gene expression, thereby inhibiting endothelial cell proliferation.
- This invention provides a method of stimulating endothelial cell proliferation comprising transfecting the endothelial cells with an effective amount of the vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TRE and one or more genes which code for a protein or peptide, wherein the Shear Stress Response Element transcriptionally regulate endothelial cell gene expression, thereby stimulating endothelial cell proliferation.
- the vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TRE and one or more genes which code for a protein or peptide, wherein the Shear Stress Response Element transcriptionally regulate endothelial cell gene expression, thereby stimulating endothelial cell proliferation.
- This invention provides a method of modulating vascular permeability in a mammal, comprising administering to said mammal an effective amount of a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide and a suitable diluent or carrier; or a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier, wherein the pharmaceutical composition is administered to the mammal in the vasculature with the proviso that the vasculature has shear stress forces, so as to permit the Shear Stress Response Element
- This invention provides a method of stimulating the formation, maturation or regression of blood vessels of a subject, comprising administering to said subject an effective amount of a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and one or more genes which code for a protein or peptide and a suitable diluent or carrier, wherein the pharmaceutical composition is administered to the mammal in the vasculature with the proviso that the vasculature has shear stress forces, so as to permit the Shear Stress Response Elements to be activated by the shear stress and transcriptionally regulate endothelial cell gene expression, thereby stimulating the formation, maturation or regression of blood vessels.
- SSRE Shear Stress Response Elements
- This invention provides a method of inhibiting the formation, maturation or regression of blood vessels of a subject, comprising administering to said subject an effective amount of a pharmaceutical composition
- a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier; or a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, wherein the pharmaceutical composition or the
- This invention provides a method of modulating genes or proteins involved in a diseases which comprises administering to a subject with the disease an effective amount of the pharmaceutical compositions and/or vectors described, above, wherein the pharmaceutical composition or vector is administered to the subject in the vasculature with the proviso that the vasculature has shear stress, so as to permit the Shear Stress Response Elements to be activated by the shear, thereby modulating genes or proteins involved in the vascular diseases.
- a method of down regulating angiogenesis comprising administering to the subject an amount of a pharmaceutical composition comprising a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide and a suitable diluent or carrier; or a vector comprising a multiple number of nucleic acids of promoter Shear Stress Response Elements (SSRE) and a nucleic acid of an antisense molecule, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, wherein the pharmaceutical composition or the vector is administered to the mammal in the vasculature with the proviso that the
- This invention provides a method of stimulating vasculogenesis and/or angiogenesis comprising contacting the cells with an effective amount of the vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TRE and a gene of interest which codes for a protein or peptide, thereby stimulating angiogenesis.
- the vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TRE and a gene of interest which codes for a protein or peptide, thereby stimulating angiogenesis.
- This invention provides a method of inhibiting ' vasculogenesis and/or angiogenesis comprising contacting the cells with an effective amount of the vector which comprises nucleic acids of Shear Stress Response Element PDGF-A, Shear Stress Response
- Element SPl or a vector which comprises nucleic acids of Shear Stress Response
- PDGF-A Shear Stress Response Element
- PDGF-B Shear Stress Response Element
- TRE and Shear Stress Response Element SPl and a nucleic acid of an inhibitor or repressor of the gene of interest, wherein the nucleic acid is an antisense molecule which hybridizes with the sense RNA strand made by the gene and thereby inhibit synthesis of the corresponding gene, ribozyme, double stranded RNA, or a nucleic acid which codes for a repressor antibody, mutant protein which inhibits the synthesis of, or activity of the protein or peptide, thereby inhibiting angiogenesis.
- a method of treating a subject having a vasculogenic and/or angiogenic disorder comprising administering to the subject an amount of the pharmaceutical composition comprises a vector which comprises nucleic acids of Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element TRE and Shear Stress Response Element SPl, or a vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, Shear Stress Response Element TRE, Shear Stress Response Element PDGF-A, Shear Stress Response Element PDGF-B, Shear Stress Response Element TRE and Shear Stress Response Element SPl or the pharmaceutical composition comprises a vector which comprises nucleic acids of Shear Stress Response Element PDGF-B, Shear Stress Response Element PDGF-B, Shear Stress Response Element SPl, and Shear Stress Response Element TR and a gene of interest which codes for a protein or peptide
- this invention provides further comprising administering to the subject an agent which acts as a vasoconstrictor, inflammatory agent, vasolidator, fibrinolytic activators, Tumor Necrosis Factor (TNF), or thrombotic factors.
- an agent which acts as a vasoconstrictor, inflammatory agent, vasolidator, fibrinolytic activators, Tumor Necrosis Factor (TNF), or thrombotic factors.
- Vasolidators are known to those skilled in the art.
- the subject invention contemplates but are not limited to the following: prostacyclin, nitric oxide, natriuretic peptide or calcium antagonists.
- Vasoconstrictors are known to those skilled in the art.
- the subject invention contemplates but are not limited to the following endothelin, thromboxan A2, angiotensin, kinins, kallikrein, and kininogen.
- subject application incorporates in its entirety by reference the following: U.S. Pat. No. 5,594,021, Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin; U.S. Pat.
- Fibrinolytic activators are known to those skilled in the art.
- subject application incorporates in its entirety by reference the following: U.S. Pat. No.4, 873,083, Fibrinolytic composition; U.S. Pat. No. 5,316,766, Thrombosis treatment with fibrinolytics and prostacyclins; U.S. Pat. No. 4,996,050, Fibrinolytic activity enhancer; U.S. Pat. No. 4,600,580, Novel enzyme derivatives; U.S. Pat. No. 5,302,390, Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment; and U.S. Pat. No. 4,568,545, Thrombolytic agent; U.S.
- Pat. No. 5,106,741 Tissue plasminogen activator (TPA) analogs.
- TPA Tissue plasminogen activator
- Thrombotic factors are known to those skilled in the art.
- subject invention application in its entirety by reference the following: U.S. Pat. No. 5,837,688, Use of thrombolytic reagents for prevention of vascular disease; U.S. Pat. No.5, 084,274, Inhibition of arterial thrombotic occlusion or thromboembolism; U.S. Pat. No.5, 509, 896, Enhancement of thrombolysis with external ultrasound; U.S. Pat. No. 5,380,299, Thrombolytic treated intravascular medical device; U.S. Pat.
- Arteriogenic, neoplastic, cardiovascular, vasculogenic and/or angiogenic disorders are known to those skilled in the art.
- the disorders include but are not limited to: cardiovascular disorders, arteriosclerosis, Monckeebrg's arteriosclerosis, atherosclerosis, diabetic arteriosclerotic disease, hypertension, arterial hypertension, renovascular hypertension, myocardial ischemic disorders, coronary artery disease, angina pectoris, myocardial infarction, occlusive arterial disorders, peripheral atherosclerotic disease, thromboangitis obliterans, functional peripheral arterial disorders, cardiac arrythmias, bundle branch block, sick sinus syndrome, cardiomyopathy, hyperlipidemia, congestive heart failure, mitral stenosis, ischemi, reperfusion, shock, restenosis, arterial inflammation, retinovasculative disorders, mascular degeneration, diabetes, hypercholesterolemia. plaque formation, osteoarthritis, method for promoting tissue repair and regeneration, wound healing,
- vasculogenic and/or angiogenic disorders include but are not limited to cancer.
- cancers included but not limited to are as follows: cancers of the epithelia (e.g., carcinomas of the pancreas, stomach, liver, secretory glands (e.g., adenocarcinoma), bladder, lung, breast, skin (e.g., fibromatosis or malignant melanoma), reproductive tract including prostate gland, ovary, cervix and uterus); cancers of the hematopoietic and immune system (e.g., leukemias and lymphomas); cancers of the central nervous, brain system and eye (e. g., gliomas, neuroblastoma and retinoblastoma); and cancers of connective tissues, bone, muscles and vasculature (e.g., hemangiomas and sarcomas)).
- epithelia e.g., carcinomas of the pancreas, stomach, liver, secretor
- this invention provides for administration of vascularizing agents when treating a subject with an angiogenic and/or vasculogenic disorder.
- Vascularization agents are known to those skilled in the art.
- such agents include but are not limited to the following:granulocyte macrophage-colony stimulating factor (GM-CSF), VEGF.
- GM-CSF granulocyte macrophage-colony stimulating factor
- VEGF vascular endothelial growth factor
- SCF Stem cell factor
- SDF- 1 stromal cell-derived factor
- G-CSF granulocyte-colony stimulating factor
- HGF Angiopoietin- 1
- MCP stromal cell-derived factor
- MMP's integrinscadherins
- Angiopoietin-2 M-CSF
- b-FGF b-FGF
- FLT-3 lignand FLT-3 lignand
- the amount of vascularization is sufficient to increase blood vessel size in the mammal.
- Methods for determining parameters of blood vessel size, e.g., length and circumference, are known in the field.
- the amount of administered modulating agent is sufficient to increase blood vessel length between from about 10% to 50%, even more preferably about 20%, as determined by standard blood vessel assay.
- the arterial tree which consists of large elastic and muscular vessels as well as arterioles and precapillaries vessels, is constantly exposed to hemodynamic forces varying widely in magnitude, frequency and direction. These forces consist of pressure acting perpendicular to the vessel wall, cyclic strain, and shear stress acting parallel to the wall, creating a frictional shear force on the surface of the endothelium.
- the magnitude of shear stress is in the range of 10-40 dynes/cm 2 , and it is over imposed with the pulsatile characteristic of the flow producing a range of shear stresses and shear stress gradients.
- the magnitude of shear stress is 1-50 dynes/cm 2 . In another embodiment the magnitude of shear stress is 2-25 dynes/cm 2 . In another embodiment the magnitude of shear stress is 10-25 dynes/cm 2 . In another embodiment the magnitude of shear stress is 2-15 dynes/cm . In another embodiment of the method the magnitude of shear stress is 5-10 dynes/cm . In another embodiment of the method the magnitude of shear stress is 2-5 dynes/cm .
- the vectors may be introduced into the desired host cells by methods known in the art, e.g., ex vivo viral vectors, particularly retroviral vectors, in vivo viral vectors, particularly defective viral vectors or adeno-associated virus vectors, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, e.g., U.S. Patent No. 5,580,859, which is incorporated by reference and Wu et al, 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263: 14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,31 1, filed March 15, 1990).
- ex vivo viral vectors particularly retroviral vectors
- in vivo viral vectors particularly defective viral vectors or aden
- the gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., 1983, Cell 33:153 Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289 Markowitz et al., 1988, J. Virol. 62:1120; Temin et al., U.S. Patent No. 5,124,263 International Patent Publication No. WO 95/07358, published March 16, 1995, by Dougherty et al.; and Kuo et al., 1993, Blood 82:845.
- a retroviral vector e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., 1983, Cell 33:153 Temin et al., U.S. Patent No. 4,650
- Retroviral vectors are especially attractive for transfecting solid tumors, since the cells of the tumor are replicating.
- Cell fusion line 18 any cell fusion combination including but not limited to cell fusion between different cell type of different tissues origin, cell fusion between different species origin, cell fusion between mammalian and yeast or mammalian and prokaryote cell type. All these methods are known in the art as methods to transfer genetic materials.
- the vector may be introduced as a single vector or with a combination of other vectors, supplementing trans activity for the SSRE vector for enhances SSRE vector activities. For example.
- SSRE containing vector can be co-introduced with another vector that will introduce another genetic material to facilitate SSRE activities, to monitor transfection efficiency, to supply a missing component to the transfected cells (supplying helper function).
- the vector can be introduced in vitro or in vivo by lipofection (lysosome fusion, including but not limited to cationic liposome, synthetic or natural lyposomes and neutral lyposomes).
- lipofection lysosome fusion, including but not limited to cationic liposome, synthetic or natural lyposomes and neutral lyposomes.
- Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for in vivo transfection of a gene encoding a marker (Feigner, et. al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84:7413-7417; see Mackey, et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:8027-8031)).
- the use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes (Feigner and Ringold, 1989, Science 337:387-388).
- lipofection to introduce exogenous genes into the specific organs in vivo has certain practical advantages.
- Lipids may be chemically coupled to other molecules for the purpose of targeting (see Mackey, et. al., 1988, supra).
- Targeted peptides e.g., hormones or neuro transmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.
- DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (see, U.S. Patent No. 5,580,859, the contents of which are hereby incorporated by reference and e.g., Wu et al., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263:14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,31 1, filed March 15, 1990).
- the present invention provides a method for the delivery of the vector to an arterial cell, blood vessel or vasculature by being carried by a microdelivery vehicle such as cationic liposomes and adenoviral vectors.
- DNA encoding different proteins may be used separately or simultaneously.
- the arterial cell in an artery or blood vessel may be contacted via a balloon catheter coated with a hydrogel polymer.
- Other treatment methods include percutaneous transluminal angioplasty (PTCA), "Cutting balloon” angioplasty, directional coronary atherectomy (DCA), rotational coronary atherectomy (RCA), Ultrasonic breaking catheter angioplasty, transluminal extraction catheter (TEC) atherectomy, Rotablator atherectomy, and excimer laser angioplasty (ELC A ).
- the vector described herein may be inserted by a single intra-femoral artery or intracoronary injection directly conducted deeply in the lumen of the one or both femoral or coronary arteries (or graft vessels) in an amount.
- U.S. Pat. No. 5792453 is hereby inco ⁇ orated in its entirety.
- plasmid DNA of any size is combined with a polylysine-conjugated antibody specific to the adenovirus hexon protein, and the resulting complex is bound to an adenovirus. vector.
- the trimolecular complex is then used to infect cells.
- the adenovirus vector permits efficient binding, internalization, and degradation of the endosome before the coupled DNA is damaged.
- Liposome/DNA complexes have been shown to be capable of mediating direct in vivo gene transfer. While in standard liposome preparations the gene transfer process is nonspecific, localized in vivo uptake and expression have been reported in tumor deposits, for example, following direct in situ administration (Nabel, 1992).
- Receptor-mediated gene transfer is accomplished by the conjugation of DNA (usually in the form of covalently closed supercoiled plasmid) to a protein ligand via polylysine.
- Ligands are chosen on the basis of the presence of the corresponding ligand receptors on the cell surface of the target cell/tissue type.
- the vector may be inserted/introduced by direct gene transfer of an expression vector.
- the vector by may implanted between the aorta and left ventricular myocardium, for induced site-directed neovascular development or administrating to the subject intrapericardial infusions. This provides exciting prospects for intervention in cardiac diseases in which myocardial oxygen supply is compromised and/or demand is increased.
- the induction of new collateral vessel formation should delay or halt the progression of coronary artery disease to myocardial infarction, as well as the advancement of ventricular hypertrophy to heart failure.
- the therapeutic compound can be delivered in a controlled release system into the vasculature.
- the vector may be administered using intravenous injections, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
- a pump may be used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321 :574 (1989)).
- polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J. Neurosurg. 71 :105 (1989)).
- a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 1 15-138 (1984)).
- a controlled release device is introduced into a subject in proximity of the site of inappropriate immune activation or a tumor.
- Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)).
- Localized administration to the target tissue is accomplished by directly injecting the vector into the target tissue or by topically applying the vector to the target tissue.
- injecting it is meant that the vector is forcefully introduced into the target tissue.
- Any suitable injection device can be used within the context of the present invention.
- Another example of an injection device which can be used within the context of the present invention includes minimally invasive injection devices. Such devices are capable of accessing the heart, for example, through small incisions of less than 5 inches and are designed to provide injections through a single lumen, in contrast to the multiple injection device described above. To allow for the need for multiple injections with a specific geometry, a marking system can be employed so that the sites of previous injections are well delineated.
- Minimally invasive injection devices can comprise injector tips which are flexible and steerable to allow access via small incisions to the curved outer surface of the heart, for example, which exists at varying angles with respect to the limited aperture window required with minimally invasive surgeries.
- Such an injection can be administered from any suitable surface of the heart (i.e., endocardially and/or epicardially).
- administration of a dose of the vector can be accomplished through a single application (e.g., a single injection or a single topical application) to the target tissue
- administration of the dose is via multiple applications of the angiogenic vector.
- the multiple applications can be 2, 3, 4, 5, or more applications, preferably 5 or more applications, more preferably 8 or more applications, and most preferably at least 10 applications.
- Multiple applications provide an advantage over single applications in that they can be manipulated by such parameters as a specific geometry defined by the location on the target tissue where each application is administered.
- the specific geometry of the multiple applications is defined by the location on the target tissue, either in two- or three-dimensional space, where each application of the ector is administered.
- the multiple applications preferably are spaced such that the points of application are separated by up to about 4 cm (e.g., about 0.5-4 cm), more preferably up to about 3 cm (e.g., about 1-3 cm), and most preferably up to about 2 cm (e.g., about 1-2 cm).
- a single application will be administered for about every 0.5-15 cm2 of the plane, more preferably for 15 about every 1-12 cm2 of the plane, and most preferably for about every 1.5-7 cm2 of the plane.
- the depth of the plane is preferably about 1-10 mm, more preferably about 2-7 mm, and most preferably about 3-5 mm.
- a single application preferably is administered for up to about 50 cm (e.g., about 0.5-50 cm of target tissue, more preferably for up to about 35 cm (e.g., about 1-35 cm of target tissue, and most preferably for up to about 15 cm (e.g., about 3-15 cm) of target tissue.
- the multiple applications can define any suitable pattern or specific geometry.
- the vector or naked SSRE nucleic acid may be administered within a biocompatible polymer.Biocompatible polymers are known to those skilled in the art, see WO 97/16176, PCT/CA96/00725 which is incorporated by reference.
- the vector or naked SSRE nucleic acid may preferably be implanted in the form of a disk, fibre or microsphere, with microsphere being the most preferred form.
- the microsphere has a diameter no greater than about 500 m, more preferably no greater than about 200 pm, and most preferably from less than about 10 ,UII to about 50 m.
- the vector or naked SSRE nucleic acid is implanted into the peripheral ischemic tissue or in blood vessels close to the ischemic tissue to stimulate the growth of blood vessels or collaterals.
- the vector or naked SSRE nucleic acid is incorporated into a wound care product applied to the surface of a wound such as a chronic wound or burn. Wound care products may be wet dressings, dry dressings, occlusive dressings, non-occlusivedressings, wound pastes, or any other product applied to a wound.
- microcapsules or microspheres which are any polymeric membrane that encloses an interior core of a different material, can be administered to a subject by various means, including implantation, injection, and infusion, via cannulas, catheters, pipette or directly through a needle from a syringe or using forceps or a trocar.
- implantation, injection, and infusion via cannulas, catheters, pipette or directly through a needle from a syringe or using forceps or a trocar.
- Preferred biocompatible polymers for use in the present invention include polyacrylates, polyphosphazenes, various vinyl polymers including polyvinyl chloride,polyacrylonitrile, polyvinyl acetate, ethylene vinyl acetate, polyvinyl alcohol copolymers, polyvinyl amine copolymers, polyimides, polyether ketones, polysulphones, siloxanes, polyurethanes and polyamides, polycarbonates, polyesters and bioresorbables such as polyanhydrides, polyorthoesters, polycaprolactones, polyamino acids, polylactic/glycolic acid copolymers and polyhydroxybutyrates.
- various vinyl polymers including polyvinyl chloride,polyacrylonitrile, polyvinyl acetate, ethylene vinyl acetate, polyvinyl alcohol copolymers, polyvinyl amine copolymers, polyimides, polyether ketones, polysulphones, siloxanes, polyurethanes and polyamide
- More preferred biocompatible polymers are polyacrylates, with hydroxyethyl methacrylate-methyl methacrylate (HEMA-MMA) and hydroxyethyl methacrylate-methyl methacrylate-methacrylic acid (HEMA-MMA-MAA).
- HEMA-MMA hydroxyethyl methacrylate-methyl methacrylate
- HEMA-MMA-MAA hydroxyethyl methacrylate-methyl methacrylate-methacrylic acid
- This invention provides administrating the vector or naked SSRE nucleic acid via intravascular catheters.
- Intravascular catheters and stents for delivery of drugs are known to those skilled in the art.
- Patent Nos. 5,180,366; 5,171,217; 5,049,132; and 5,021,044;and PCT Publications WO 93/08866, WO 92/1 1895 and WO 97/123256 which are hereby inco ⁇ orated by reference.
- Tissues to be treated by the present invention will typically be adjacent to blood vessels, within the blood vessel, or more typically being adjacent to coronary and peripheral arteries, where the vector or naked SSRE nucleic acid is delivered transmurally within the adjacent blood vessel to promote angiogenesis from the delivery site within the blood vessel into the surrounding tissue.
- the target tissue will usually be ischemic, i.e., deprived of blood flow, but the present invention might also find use with promoting angiogenesis in non-ischemic tissues.
- body lumen will generally refer to blood vessels, including portions of the arterial vasculature and venous vasculature. Body lumen wall includes the neointimal, intimal, medial, adventitial and perivascular spaces, adjacent to the target site.
- delivery of the vector according to the methods of the present invention could be performed after balloon angioplasty to enhance blood perfusion into ischemic tissue surrounding the treated stenotic region.
- Delivery of vector or naked SSRE nucleic acid could also be combined with delivery of other therapeutic agents intended for treating coronary artery disease, such as anti-5 thrombotic and fibrinolytic agents.
- balloon catheters having expandable distal ends capable of engaging the inner wall of a blood vessel and infusing an angiogenic factor directly therein are well-described in the patent literature. See, for example, U.S.Patent Nos.
- Ultrasonically assisted drug delivery catheters (phonophoresis devices) are described in U.S. Patent Nos. 15 5,362,309; 5,318,014; and 5,315,998.
- Other iontophoresis and phonophoresis drug delivery catheters are described in U.S. Patent Nos. 5,304,120; 5,282,785; and 5,267,985.
- sleeve catheters having drug delivery lumens intended for use in combination with conventional angioplasty balloon catheters are described in U.S. Patent Nos. 5,364,356 and 5,336,178.
- the vector or naked SSRE nucleic acid could be delivered by applying a thin layer of a hydrogel,glycosaminoglycans, or other polymeric carrier matrix to the endoluminal wall at the target location.
- the polymeric carrier will be biodegradable or bioeluting and serve as a temporary wall support while the vector or naked SSRE nucleic acid are released over time.
- compositions of the present invention are particularly suited to administration to a mammal, preferable a human subject.
- pharmaceutical composition could mean therapeutically effective amounts of the vector of the invention together with suitable diluents, preservatives, solubilizers, emulsifiers, adjuvant and/or carriers.
- a “therapeutically effective amount” as used herein refers to that amount which provides a therapeutic effect for a given condition and administration regimen.
- compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCL, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent abso ⁇ tion to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or inco ⁇ oration of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, pol
- compositions of the invention inco ⁇ orate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.
- pharmaceutical composition is administered parenterally, intratumorally, paracancerally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intravascularly, subcutaneously, intraperitonealy, intraventricularly, intracranially.
- pharmaceutically acceptable carrier include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents examples include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobial, antioxidants, collating agents, inert gases and the like.
- adjuvant refers to a compound or mixture that enhances the immune response to an antigen.
- An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al., Immunology, Second Ed., 1984, Benjamin/Cummings: Menlo Park, California, p. 384).
- a primary challenge with an antigen alone, in the absence of an adjuvant will fail to elicit a humoral or cellular immune response.
- Adjuvant include, but are not limited to, complete Freud's adjuvant, incomplete Freud's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol.
- the adjuvant is pharmaceutically acceptable.
- Controlled or sustained release compositions include formulation in lipophilic depots (e.g. fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g. poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention inco ⁇ orate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral. Suitable excipients are, for example,. water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.
- auxiliary substances such as wetting or emulsifying agents, pH buffering
- An active component can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms.
- Pharmaceutically acceptable salts include the acid addition salts and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
- the pharmaceutically acceptable form of the composition includes a pharmaceutically acceptable carrier.
- a therapeutically effective dosage of the active component is provided.
- a therapeutically effective dosage can be determined by the ordinary skilled medical worker based on patient characteristics (age, weight, sex, condition, complications, other diseases, etc.), as is well known in the art. Furthermore, as further routine studies are conducted, more specific information will emerge regarding appropriate dosage levels for treatment of various conditions in various patients, and the ordinary skilled worker, considering the therapeutic context, age and general health of the recipient, is able to ascertain proper dosing. Generally, for intravenous injection or infusion, dosage may be lower than for intraperitoneal, intramuscular, or other route of administration.
- the dosing schedule may vary, depending on the circulation half-life, and the formulation used.
- the compositions are administered in a manner compatible with the dosage formulation in the therapeutically effective amount. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous, infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.
- This invention provides a method for detecting shear stress or a shear stress related condition in a subject, comprising administering to the subject an amount of the vector which comprises one or more Shear Stress Response Element and a reporter gene, wherein the gene is activated in a shear stress environment, thereby detecting shear stress or a shear stress related condition in the subject.
- This invention provides a method for screening test compounds for the ability to regulate endothelial cell expression or angiogenesis and/or vasculogenesis comprising: (a) contacting a endothelial cells with the compound to be tested; (b) determining the amount or expression of the endothelial cells or the amount of angiogenesis and/or vasculogenesis produced as a result of the test compound; (c) stimulating endothelial cells by introduction of the vector provided herein; (d) determining the amount or expression of the endothelial cells or the amount of angiogenesis and/or vasculogenesis produced as a result of the vector; (e) comparing the amount of angiogenesis and/or vasculogenesis produced as a result step (b) to that of step (d), wherein an increased amount of expression of the endothelial cells or the amount of angiogenesis and/or vasculogenesis of the test compound means that the test compound regulates endothelial cell expression angiogenesis and/or vasculogenesis.
- test composition is any composition such as a gene, SSRE, a nucleic acid sequence, a polypeptide, peptide fragment or composition created through the use of a combinatorial library or other combinatorial process that can be assayed for its ability to function in given capacity or compound which mimics the activity of the complex. Often such a test composition, nucleic acid sequence or polypeptide is, because of its sequence or structure, suspected of being able to function in a given capacity.
- Any screening technique known in the art can be used to screen for regulators or modulators of angiogenesis and/or vasculogenesis. Identification and screening of antagonists or agonist is further facilitated by comparing the result of the test composition with the result of the vector described hereinabove These techniques provide for the rational design or identification of agonists and antagonists.
- U.S. Pat. No. 5,165,938, Screening assays for compounds is incorporated in its entirety.
- This invention provides methods to monitor shear stress activities, to screen and select for target genes, for gene therapy in other organs and methods of identifying and describing genes which are differentially expressed in vascular disease states, relative to their expression in normal, or non-cardiovascular disease states and a method for the identification and therapeutic use of compounds as treatments of vascular disease.
- This invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of vascular diseases, and for monitoring the efficacy of compounds in clinical trials. Because the SSRE of this invention are modulated, i.e up-regulated or down-regulating, treatment methods can be designed to enhance or increase the expression of these genes which are coupled to the SSREs, particularly in endothelial cells. In addition, detecting expression of these genes in low amounts of normal expression provides for the diagnosis of disease.
- genes which are involved in vascular disease may represent genes which are differentially expressed in vascular disease conditions relative to their expression in normal, or non-cardiovascular disease conditions.
- differentially expressed genes may represent "target” and/or “fingerprint” genes.
- “Differential expression” as used herein refers to both quantitative as well as qualitative differences in the genes' temporal and/or tissue expression patterns.
- a differentially expressed gene may have its expression activated or completely inactivated in normal versus vascular disease conditions, or under control versus experimental conditions.
- Such a qualitatively regulated gene will exhibit an expression pattern within a given tissue or cell type which is detectable in either control or cardiovascular disease subjects, but is not detectable in both.
- Detectable refers to an RNA expression pattern which is detectable via the standard techniques of differential display, reverse transcriptase- (RT-) PCR and/or Northern analyses, which are well known to those of skill in the art.
- a differentially expressed gene may have its expression modulated, i.e., quantitatively increased or decreased, in normal versus cardiovascular disease states, or under control versus experimental conditions.
- the degree to which expression differs in normal versus cardiovascular disease or control versus experimental states need only be large enough to be visualized via standard characterization techniques, such as, for example, the differential display technique described below.
- standard characterization techniques such as, for example, the differential display technique described below.
- Other such standard characterization techniques by which expression differences may be visualized include but are not limited to quantitative RT-PCR and Northern analyses.
- Differentially expressed genes may be further described as target genes and/or finge ⁇ rint genes.
- “Finge ⁇ rint gene,” as used herein, refers to a differentially expressed gene whose expression pattern may be utilized as part of a prognostic or diagnostic cardiovascular disease evaluation, or which, alternatively, may be used in methods for identifying compounds useful for the treatment of cardiovascular disease.
- a finge ⁇ rint gene may also have the characteristics of a target gene.
- a target gene may also have the characteristics of a fingerprint gene.
- a variety of methods may be utilized for the identification of genes which are involved in cardiovascular disease which are known to those skilled in the art.
- test cells Cultured HUVEC monolayers are exposed to laminar sheer stress by in a specialized apparatus containing liquid culture medium, may also be compared to unrelated cells (e.g., fibrobiasts) that are also treated with the compound, in order to screen out generic effects on gene expression that might not be related to the disease.
- unrelated cells e.g., fibrobiasts
- Such generic effects might be manifest by changes in gene expression that are common to the test cells and the unrelated cells upon treatment with the compound.
- RNA may be isolated from one or more tissues of the subjects utilized in paradigms such as those described earlier in this Section. RNA samples are obtained from tissues of experimental subjects and from corresponding tissues of control subjects. Any RNA isolation technique which does not select against the isolation of mRNA may be utilized for the purification of such RNA samples. See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel, F. M. et al., eds., 1987-1993, Current Protocols in Molecular Biology, John Wiley & Sons, Inc. New York, both of which are inco ⁇ orated herein by reference in their entirety.
- tissue samples may readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski, P. (1989, U.S. Pat. No. 4,843,155), which is incorporated herein by reference in its entirety.
- Transcripts within the collected RNA samples which represent RNA produced by differentially expressed genes may be identified by utilizing a variety of methods which are well known to those of skill in the art. For example, differential screening (Tedder, T. F. et al., 1988, Proc. Natl. Acad. Sci. USA 85:208-212), subtractive hybridization (Hedrick, S. M. et al., 1984, Nature 308: 149-153; Lee, S. W. et al., 1984, Proc. Natl. Acad. Sci. USA 88:2825), and, preferably, differential display (Liang, P., and Pardee, A. B., 1993, U.S. Pat. No. 5,262,311, which is inco ⁇ orated herein by reference in its entirety), may be utilized to identify nucleic acid sequences derived from genes that are differentially expressed.
- Subtractive hybridization techniques generally involve the isolation of mRNA taken from two different sources, e.g., control and experimental tissue, the hybridization of the mRNA or single-stranded cDNA reverse-transcribed from the isolated mRNA, and the removal of all hybridized, and therefore double-stranded, sequences.
- the remaining non-hybridized, single-stranded cDNAs potentially represent clones derived from genes that are differentially expressed in the two mRNA sources.
- Such single-stranded cDNAs are then used as the starting material for the construction of a library comprising clones derived from differentially expressed genes.
- the differential display technique describes a procedure, utilizing the well known polymerase chain reaction (PCR; the experimental embodiment set forth in Mullis, K. B., 1987, U.S. Pat. No. 4,683,202) which allows for the identification of sequences derived from genes which are differentially expressed.
- PCR polymerase chain reaction
- isolated RNA is reverse-transcribed into single-stranded cDNA, utilizing standard techniques which are well known to those of skill in the art.
- Primers for the reverse transcriptase reaction may include, but are not limited to, oligo dT-containing primers, preferably of the reverse primer type of oligonucleotide described below.
- this technique uses pairs of PCR primers, as described below, which allow for the amplification of clones representing a random subset of the RNA transcripts present within any given cell. Utilizing different pairs of primers allows each of the mRNA transcripts present in a cell to be amplified. Among such amplified transcripts may be identified those which have been produced from differentially expressed genes.
- PCR reaction conditions should be chosen which optimize amplified product yield and specificity, and, additionally, produce amplified products of lengths which may be resolved utilizing standard gel electrophoresis techniques.
- reaction conditions are well known to those of skill in the art, and important reaction parameters include, for example, length and nucleotide sequence of oligonucleotide primers as discussed above, and annealing and elongation step temperatures and reaction times.
- the pattern of clones resulting from the reverse transcription and amplification of the mRNA of two different cell types is displayed via sequencing gel electrophoresis and compared. Differences in the two banding patterns indicate potentially differentially expressed genes.
- differential expression of such putatively differentially expressed genes should be corroborated. Corroboration may be accomplished via, for example, such well known techniques as Northern analysis and/or RT-PCR.
- methods may be employed which result in the simultaneous identification of pathway genes which encode the protein interacting with a protein involved in cardiovascular disease.
- These methods include, for example, probing expression libraries with labeled protein known or suggested to be involved in cardiovascular disease, using this protein in a manner similar to the well known technique of antibody probing of lambda gt 1 1 libraries.
- Compounds identified via assays such as those described herein may be useful, for example, in elaborating the biological function of the target gene product, and for ameliorating diseases discussed above.
- compounds that interact with the target gene product may include compounds which accentuate or amplify the activity of the bound target gene protein.
- animal-based cardiovascular disease systems such as those described, may be used to identify compounds capable of ameliorating cardiovascular disease symptoms.
- Such animal models may be used as test substrates for the identification of drugs, pharmaceuticals, therapies, and interventions which may be effective in treating cardiovascular disease.
- animal models may be exposed to a compound, suspected of exhibiting an ability to ameliorate cardiovascular disease symptoms, at a sufficient concentration and for a time sufficient to elicit such an amelioration of cardiovascular disease symptoms in the exposed animals.
- the response of the animals to the exposure may be monitored by assessing the reversal of disorders associated with cardiovascular disease, for example, by counting the number of atherosclerotic plaques and/or measuring their size before and after treatment.
- Antisense and ribozyme molecules which inhibit expression of the target gene may also be used in accordance with the invention to inhibit the aberrant target gene activity.
- the compounds which may exhibit the ability to ameliorate cardiovascular disease symptoms are antisense, ribozyme, and triple helix molecules.
- the present invention provides a kit comprising the all the essential materials and reagents required.
- This generally will comprise selected expression constructs.
- kits will comprise distinct containers for each individual reagent.
- the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being particularly preferred.
- the expression construct may be formulated into a pharmaceutically acceptable syringeable composition.
- the container means may itself be an inhalent, syringe, pipette, eye dropper, or other such like apparatus, from which the formulation may be applied to an infected area of the body, such as the lungs, injected into an animal, or even applied to and mixed with the other components of the kit.
- the components of the kit may also be provided in dried or lyophilized forms. When reagents or components are provided as a dried form, reconstitution generally is by the addition of a suitable solvent. It is envisioned that the solvent also may be provided in another container means.
- kits of the present invention also will typically include a means for containing the vials in close confinement for commercial sale such as, e.g., injection or blow-molded plastic containers into which the desired vials are retained.
- a means for containing the vials in close confinement for commercial sale such as, e.g., injection or blow-molded plastic containers into which the desired vials are retained.
- the kits of the invention also may comprise, or be packaged with, an instrument for assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal.
- an instrument may be an inhalent, syringe, pipette, forceps, measured spoon, eye dropper or any such medically approved delivery vehicle.
- EXAMPLE 1 Construction of "synthetic" shear stress responsive hybrid promoter constructs based on known SSREs.
- Cone - Plate shear stress apparatus A cone-plate viscometer was used, the design of which and the operating parameters have been described in details (26, 36). Shear stress is produced in the fluid contained between a stationary base plate and a rotating cone. By adjusting the cone angle, the viscosity of the medium and the cone rotational speed a wide broad of shear stress magnitudes (1-50 dynes/cm) and patterns (laminare, turbulent, disturbed-laminar and oscillatory) can be achieved. Confluent endothelial monolayers can be grown either on 11 mm in diameter twelve tissue culture coated coverslips to achieve multiple sampling under the same flow and medium conditions, or alternatively, on a 17 cm in diameter tissue culture coated coverslip for molecular biology procedures requiring high cell quantities.
- SSREs Four positive SSREs were defined and tested, which include the PDGF/B SSRE which binds NFkB and NFAT, the PDGF/A SSRE which binds Spl and Egrl, the MCP-1 TRE which is binding site for fos and jun and the tissue factor SSRE, which is a binding site for Spl. Interestingly, most of these promoters contain more than one of the described SSREs. PDGF-B promoter contains a binding site for fos and jun and an spl binding site in addition to the PDGF/B-SSRE. MCP-1 encodes for the PDGF/B-SSRE in addition to its TRE site.
- Tissue factor promoter contains NFkB, fos and jun binding sites, in addition to its spl/SSRE site. Shear stress responsiveness in vivo, is the result of the cooperative action of several SSREs in each promoter.
- the vector pGL2-promoter as shown in Figure 1 , containing the luciferase gene and the SV40 promoter (Promega, Madison, WI, U.S.A) was used as a backbone to all of the described constructs.
- This oligonucleotide contains the PDGF-B/SSRE sequence (GAGACCCCC) twice, the Sp-1 binding site (GGGGCGGGGCG) twice, the TRE site (TGACTCC) twice and polylinkers to the restrictions enzymes Miul and Xhol.
- This oligonucleotide contains the Spl /Egrl sequence from the PDGF-A promoter (GGGGGCGGGGGCGGGGG) twice, the PDGF-B/SSRE once (GAGACCCCC), the TRE site (TGACTCC) once, and polylinkers to the restriction enzymes Xhol and Bglll.
- These constructs were ligated 5 'to the SV40 promoter (both NR1/NR2 and NR3/NR4) to create the vectors 5' NR1/NR2-Luc and 5' NR3 NR4-Luc and also 3' to the luciferase gene (3' NR3/NR4-Luc) to test the positional effect of the SSREs.
- These constructs were used to transfect endothelial cells, and their expression was compared to already existing hybrid promoters containing each of the SSREs alone.
- several commercially available transfection kits as well as a modified calcium phosphate method adapted by to suit endothelial cells were used. In these experiments three kits were used: The Tfx 20 and 50 (Promega, U.S.A). Fugene (Gibco-BRL, U.S.A) and Effectine (Qiagene, U.S.A).
- Endothelial cells from arterial and capillary origin Bovine Aortic Endothelial cells -BAEC, and Bovine brain Capillary Edothelial cells - BBC were used for transfecion.
- the efficiencies of transfection of BAEC with the various techniques were: Modified calcium phosphate (concentration of sodium hydrogen phosphate 1.4 mM),22%, Effectine - 19%, Fugene - 15%, Tfx 20 - 16%, and Tfx 50-20%.
- the efficiencies of transfection of BBC with the various methods were: Modified Calcium phosphatase: 8%, Effectine - 15%, Fugene - 15%, and Tfx 20 - 13% Tfx 50 - 7%.
- Endothelial cells were transfected in triplicate with three constructs: NR1/2 which contains the combination of all four SSREs, SSRE-Luc which contains a single copy of the PDGF-B/SSRE and the core plasmid PGL, and co-transfected with the Renilla luciferase vector.
- Two days after transfection the cells were transferred to a medium containing 5% calf serum and either incubated under static conditions or exposed to shear stress (10 dynes/cm , 2 hrs). The cells were extracted and the ratio luciferase/renilla luciferase was calculated. The induction of expression was calculated for the average ratio of the triplicates in shear stress versus, static experiments.
- Table 1 The induction of SSRE-hybrid promoter vectors by shear stress.
- the vector pGL3 -enhancer as shown in Figure 2, containing the luciferase gene and the SV40 promoter (Promega, Madison, WI, U.S.A) was used as a backbone to all of the described constructs.
- This oligonucleotide contains the Spl /Egrl sequence from the PDGF-A and from the TF promoter (GGGGGCGGGGGCGGGGG) twice, the PDGF-B/SSRE once (GAGACCCCC), the TRE site (TGACTCC) once, and polylinkers to the restriction enzymes Xhol and Bgll.
- -These constructs were ligated 5'to the SV40 promoter (both NR1/NR2 and NR3/NR4) to create the vectors 5' NR1/NR2-Luc and 5' NR3/NR4-Luc and also 3' to the luciferase gene (3' NR3/NR4-Luc) to test the positional effect of the SSREs.
- These constructs were used to transfect endothelial cells, and their expression was compared to already existing hybrid promoters containing each of the SSREs alone.
- This oligonucleotide contains the PDGF-B/SSRE sequence (GAGACCCCC) three times, the Sp-1 binding site (GGGGCGGGGCG) twice, the TRE site (TGACTCC) twice and polylinkers to the restrictions enzymes Miul and Xhol and
- This oligonucleotide contains the Spl /Egrl sequence from the PDGF-A promoter (GGGGGCGGGGGCGGGGG) twice, the PDGF-B/SSRE once (GAGACCCCC), the TRE site (TGACTCC) once, and polylinkers to the restriction enzymes Xhol and Bgll.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99961261A EP1141266A4 (en) | 1998-12-24 | 1999-12-23 | Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof |
JP2000591168A JP2002533113A (en) | 1998-12-24 | 1999-12-23 | Expression vector containing a plurality of shear stress response elements (SSREs) and a gene of interest, and uses thereof |
AU17954/00A AU1795400A (en) | 1998-12-24 | 1999-12-23 | Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11386398P | 1998-12-24 | 1998-12-24 | |
US09/220,510 US6440726B1 (en) | 1998-12-24 | 1998-12-24 | Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment |
US60/113,863 | 1998-12-24 | ||
US09/220,510 | 1998-12-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000039275A2 true WO2000039275A2 (en) | 2000-07-06 |
WO2000039275A3 WO2000039275A3 (en) | 2000-10-26 |
Family
ID=26811564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL1999/000702 WO2000039275A2 (en) | 1998-12-24 | 1999-12-23 | Multiple shear stress responsive elements (ssre) and methods of use thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1141266A4 (en) |
JP (1) | JP2002533113A (en) |
AU (1) | AU1795400A (en) |
WO (1) | WO2000039275A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247714B2 (en) | 2001-10-16 | 2007-07-24 | Atherogenics, Inc. | Protection against oxidative stress and inflammation by a cytoprotective response element |
CN109371046A (en) * | 2018-09-29 | 2019-02-22 | 上海交通大学 | A kind of induction type oxin-antitoxin element for thermophilic microorganism genetic manipulation |
CN112656763A (en) * | 2020-12-29 | 2021-04-16 | 吉林大学 | Preparation method of drug-loaded nano-micelle based on shear force response |
USD1018557S1 (en) | 2019-05-17 | 2024-03-19 | Opsens, Inc. | Display screen or portion thereof with graphical user interface |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101678074B (en) * | 2007-03-22 | 2014-04-23 | 韩国加图立大学产学合作基金会 | Novel use of ec-sod and method for preparing thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834306A (en) * | 1994-12-23 | 1998-11-10 | Sri International | Tissue specific hypoxia regulated therapeutic constructs |
US5834248A (en) * | 1995-02-10 | 1998-11-10 | Millennium Pharmaceuticals Inc. | Compositions and methods using rchd534, a gene uregulated by shear stress |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001517081A (en) * | 1997-04-08 | 2001-10-02 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ アドミニストレイター オブ ザ ナショナル アエロノーティクス アンド スペイス アドミニストレイション(ナサ) | Production of functional proteins: balance between shear stress and gravity |
-
1999
- 1999-12-23 JP JP2000591168A patent/JP2002533113A/en active Pending
- 1999-12-23 WO PCT/IL1999/000702 patent/WO2000039275A2/en not_active Application Discontinuation
- 1999-12-23 EP EP99961261A patent/EP1141266A4/en not_active Withdrawn
- 1999-12-23 AU AU17954/00A patent/AU1795400A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834306A (en) * | 1994-12-23 | 1998-11-10 | Sri International | Tissue specific hypoxia regulated therapeutic constructs |
US5834248A (en) * | 1995-02-10 | 1998-11-10 | Millennium Pharmaceuticals Inc. | Compositions and methods using rchd534, a gene uregulated by shear stress |
Non-Patent Citations (3)
Title |
---|
RESNICK ET AL.: 'Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element' PROC. NATL. ACAD. SCI. USA vol. 90, May 1993, pages 4591 - 4595, XP002075319 * |
See also references of EP1141266A2 * |
SHYY ET AL.: 'The cis-acting phorbol ester "12-0-tetradecanoylphorbol 13-acetate"-responsive element is involved in shear stress-induced monocyte chemotactic protein 1 gene expression' PROC. NATL. ACAD. SCI. USA vol. 92, August 1995, pages 8069 - 8073, XP002928997 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247714B2 (en) | 2001-10-16 | 2007-07-24 | Atherogenics, Inc. | Protection against oxidative stress and inflammation by a cytoprotective response element |
CN109371046A (en) * | 2018-09-29 | 2019-02-22 | 上海交通大学 | A kind of induction type oxin-antitoxin element for thermophilic microorganism genetic manipulation |
USD1018557S1 (en) | 2019-05-17 | 2024-03-19 | Opsens, Inc. | Display screen or portion thereof with graphical user interface |
CN112656763A (en) * | 2020-12-29 | 2021-04-16 | 吉林大学 | Preparation method of drug-loaded nano-micelle based on shear force response |
CN112656763B (en) * | 2020-12-29 | 2022-07-15 | 吉林大学 | Preparation method of drug-loaded nano-micelle based on shear force response |
Also Published As
Publication number | Publication date |
---|---|
JP2002533113A (en) | 2002-10-08 |
AU1795400A (en) | 2000-07-31 |
EP1141266A2 (en) | 2001-10-10 |
EP1141266A4 (en) | 2002-09-25 |
WO2000039275A3 (en) | 2000-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6121246A (en) | Method for treating ischemic tissue | |
US5652225A (en) | Methods and products for nucleic acid delivery | |
USRE37933E1 (en) | Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis | |
US8916378B2 (en) | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy | |
JP5856059B2 (en) | SDF-1 delivery for treating ischemic tissue | |
Gorski et al. | Inhibition of endothelial cell activation by the homeobox gene Gax | |
JP2004500880A (en) | Liver-specific gene expression cassette and method of use | |
JP3684371B2 (en) | Endothelial cell proliferation inhibitor and use thereof | |
US5658729A (en) | Method, reagent and kit for evaluating susceptibility to premature atherosclerosis | |
US6440726B1 (en) | Expression vectors comprising multiple shear stress responsive elements (SSRE) and methods of use for treating disorders related to vasculogenesis and/or angiogenesis in a shear stress environment | |
EP1141266A2 (en) | Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof | |
JP4733337B2 (en) | Recombinant viral and non-viral vectors containing human urokinase-type plasminogen activator gene and various types of fibrosis such as liver fibrosis, renal fibrosis, pulmonary fibrosis, pancreatic fibrosis, cardiac fibrosis, And its usefulness in the treatment of hypertrophic scars | |
AU2001270614B2 (en) | Chimeric promoters for controlling expression in smooth muscle cells | |
US20130210898A1 (en) | Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same | |
Kameda et al. | Kidney-targeted naked DNA transfer by retrograde injection into the renal vein in mice | |
US7569543B2 (en) | Compositions of Angiopoietin, fragments, mutants and analogs thereof and uses of the same | |
US20130164262A1 (en) | Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same | |
Ehsan et al. | Antisense and gene therapy to prevent restenosis | |
JP2002535372A (en) | Plasminogen kringle 4 region fragment and methods of use | |
Simmons et al. | Adenovirally Mediated Gene Transfer of Functional Human Tissue–type Plasminogen Activator to Murine Lungs | |
Ojalvo et al. | Therapeutic angiogenesis following intramuscular gene transfer of vascular endothelialgrowth factor 121 in a dog model of hindlimb ischemia | |
Beck Jr | Cell-cell interactions and microenvironmental influences in vascular development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 17954 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 591168 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999961261 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999961261 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999961261 Country of ref document: EP |